Compare
Armata Pharmaceuticals, Inc. vs Alpha Cognition Inc. vs Protalix BioTherapeutics, Inc. vs Aligos Therapeutics, Inc.
| Latest fiscal year | Armata Pharmaceuticals, Inc. ARMP | Alpha Cognition Inc. ACOG | Protalix BioTherapeutics, Inc. PLX | Aligos Therapeutics, Inc. ALGS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $10.22M | $52.74M | $2.19M |
| Revenue growth (YoY) | n/a | n/a | -1.2% | -39.5% |
| Gross margin | n/a | 94.1% (computed) | 48.8% (computed) | n/a |
| Operating margin | n/a | -221.7% | -10.4% | n/m |
| Net margin | n/a | -202.2% | -12.5% | n/m |
| Net income | -$173.80M | -$20.67M | -$6.60M | -$24.19M |
| EPS (Diluted) | -$4.80 | -$1.18 | -$0.08 | -$2.45 |
| Operating cash flow | -$25.76M | -$20.38M | -$11.99M | -$82.50M |
| Free cash flow | -$26.30M | -$20.67M | -$13.63M | n/a |
| Cash & equivalents | $8.69M | $66.05M | $14.68M | $18.30M |
| Total assets | $76.88M | $79.73M | $82.35M | $88.53M |
| Total liabilities | $295.48M | $17.20M | $34.12M | $34.99M |
| Shareholders' equity | -$218.60M | $62.53M | $48.23M | $53.55M |
| Return on year-end equity | n/a | -33.1% | -13.7% | -45.2% |
| Shares outstanding | 36.43M | 21.74M | 80.43M | 6.18M |
Revenue, most recent five fiscal years
| Fiscal year | Armata Pharmaceuticals, Inc. | Alpha Cognition Inc. | Protalix BioTherapeutics, Inc. | Aligos Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $10.22M Ended 2025-12-31 | $52.74M Ended 2025-12-31 | $2.19M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $53.40M Ended 2024-12-31 | $3.61M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $65.49M Ended 2023-12-31 | $6.19M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $47.64M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $38.35M Ended 2021-12-31 | $0 Ended 2021-12-31 |